Emilie Toresson Grip

Karolinska Institutet

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Anders Helander

Karolinska University Hospital

SWEDEN

View details

Rickard Strandberg

Karolinska Institutet

SWEDEN

View details

Hannes Hagström

Professor, Senior Consultant Hepatologist

Karolinska Institutet

SWEDEN

View details

Berit Schiøttz Christensen

University of Southern Denmark

DENMARK

View details

Juan Vaz

Lund University

SWEDEN

View details

Axel Wester

Karolinska University Hospital

SWEDEN

View details

Ying Shang

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Emilie Toresson Grip

Research Interests

Explore related searches

Contact this professor

Articles (10)

Potential issues with implementation of EASL-EASD-EASO guidelines on management of MASLD in patients with type 2 diabetes in Sweden

Number of metabolic syndrome traits adds little to prediction of major adverse liver outcomes on top of FIB-4 in patients with type 2 diabetes

Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes

Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes

Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.

Economic burden of osteoarthritis - multi-country estimates of direct and indirect costs from the BISCUITS study

Burden of disease and management of osteoarthritis and chronic low back pain

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.

Problematic opioid use among osteoarthritis patients with chronic post-operative pain after joint replacement: analyses from the BISCUITS study.

Collaborators (7)

Anders Helander

Rickard Strandberg

Hannes Hagström

Berit Schiøttz Christensen

Juan Vaz

Axel Wester

Ying Shang

Make your next move.